logo dark logoo light logo
  • 主頁
  • AM1480
  • AM1380
  • 華語電視 Sino TV
  • 聯繫我們
  • 抗疫送暖
logo dark logoo light logo
  • 主頁
  • AM1480
  • AM1380
  • 華語電視 Sino TV
  • 聯繫我們
  • 抗疫送暖
mobile logo
  • 主頁
  • AM1480
  • AM1380
  • 華語電視 Sino TV
  • 聯繫我們
  • 抗疫送暖
July 22, 2021
Uncategorized

14州住院數創新高 專家憂未來6-12周疫情最黑暗

美國每日新增新冠病例持續攀升,有14州的新冠住院數創新高紀錄,明尼蘇達大學傳染病研究與政策中心主任歐斯特宏(Michael Osterholm)警告,接下來數月將是「整場疫情最黑暗的日子」。

美國七天平均每日新增新冠病例在周一達58,300例,創八月第一周以來新高紀錄,並且接近七月創下的6萬7200例的紀錄。每日新增確診數字比9月12日增加了70%。

歐斯特宏在「國家廣播公司」(NBC)節目上,被主持人問到白宮推動「群體免疫」引發的爭議,他坦承自己並不像川普政府那樣樂觀。他說:「我們的確可望掌握疫苗與療法,但從時間上來看,接下來六至12周將是整場疫情最黑暗日子;直到明年年初至第三季之前,疫苗都不會以有意義的方式供應使用;而就算到了那個時候,全美也有約半數民眾會對於接種持懷疑態度。」

歐斯特宏將這種懷疑論歸咎於「訊息傳遞方面的重大問題」;他解釋道,國人目前沒有一個「榜樣」或「統一的」意見來帶領大家度過疫情。他說:「民眾不知道可以相信什麼,而那是我們今後的重大挑戰,我們提供給公眾的訊息,必須反映科學與現實。」

歐斯特宏還說,群體免疫的目標,在讓民眾接受預防接種的情況下達到最好,而不只是讓民眾感染病毒,但這就需要公眾支持。

分享:

SHARE THIS ARTICLE

by admin
0
0
Previous post 終場辯論禁止插嘴 對手回答時另1人麥克風消音
Next post 最高法院大法官提名下週一投票 兩黨意見分裂

即時新聞

聯邦政府停擺兩週 白宮警告將繼續裁員

October 14, 2025

國防部公佈新新聞政策 多個新聞機構大力反對

October 14, 2025

勞資雙方未達協議 百老匯劇院或陷入停擺

October 14, 2025

布碌崙11歲男孩被車撞倒致傷 司機肇事逃逸

October 14, 2025

調查:美小企業樂觀情緒降至3個月低點

October 14, 2025
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

SAVE & ACCEPT

Terms and Conditions - Privacy Policy